Simeprevir sodium is a pharmaceutical compound primarily used as an antiviral medication for the treatment of chronic hepatitis C virus (HCV) infection. It is a protease inhibitor that specifically targets the NS3/4A protease of the HCV, thereby inhibiting viral replication. The compound is characterized by its high potency against various HCV genotypes and is often used in combination with other antiviral agents to enhance therapeutic efficacy. Simeprevir sodium is typically administered orally and is known for its favorable pharmacokinetic profile, including good absorption and a relatively long half-life, which allows for once-daily dosing. In terms of safety, it may cause side effects such as fatigue, nausea, and skin rashes, and it is contraindicated in patients with severe liver impairment. The chemical structure of Simeprevir sodium includes a sulfonamide group, contributing to its solubility and bioavailability. Overall, Simeprevir sodium represents a significant advancement in the treatment of hepatitis C, offering improved outcomes for patients when used as part of a comprehensive antiviral regimen.

Simeprevir Sodium

Simeprevir sodium

Simeprevir is a drug for the treatment and cure of hepatitis C.

CAS 1241946-89-3: Simeprevir Sodium

Simeprevir sodium

Ref: 3D-FS158423

Simeprevir sodium

Ref: TM-T21341